Search Results

You are looking at 41 - 50 of 372 items for :

  • "therapeutics" x
  • Refine by Access: All x
Clear All
Full access

Predictive Biomarkers in Advance of a Companion Drug: Ahead of Their Time?

Robin K. Kelley, Chloe Atreya, Alan P. Venook, and Phillip G. Febbo

remain in clinical development with unproven clinical benefit. The discordant commercial maturation of therapeutics and their companion biomarkers arises largely from disparate development and regulatory environments and, ultimately, leads to the question

Full access

EPR21-039: Socioeconomic Disparities in Receipt of Care in Lung Cancer

Evangelia Valilis, Catherine Yip, Laura Prichett, Catherine Burdalski, and Josephine Feliciano

care. This study aimed to evaluate the association of socio-demographic factors with lung cancer treatment at a large academic center that serves a diverse patient population. In the era of improved outcomes related to improved therapeutics such as

Full access

YIA20-006: Preclinical Pediatric MATCH

Elizabeth Stewart, Kaley Blankenship, Lauren Hoffmann, and Burgess Freeman

presented at the annual meeting. Conclusions: The testing of molecularly targeted therapeutics in PDX models of pediatric solid tumors is feasible and may be beneficial to understanding the driver mutations and underlying biology of these malignancies. We

Full access

QIM24-183: Novel Therapies in the Oncology Care Model: A Profile in Review.

Puneeth Indurlal and Lalan S. Wilfong

newer indications based on FDA approvals. Novel therapy status was also applied based on patient age for some drugs (dasatinib). Conclusions: The novel therapy status highlights the fast-paced evolution of therapeutics in Oncology. The cascading FDA

Full access

HSR24-135: Community Oncologists’ Perceptions on the Evolving Role of Surrogate Endpoints in Oncologic Clinical Trials

Brooke Leon, Robert N. Bone, Yolaine Jeune-Smith, and Bruce Feinberg

trust for clinical application. Over half of respondents indicated that the use of surrogate endpoints has increased treatment options (77%) and decreased time-to-market for therapeutics (62%). Notably, nearly all respondents (96%) indicated that

Full access

QIM23-126: Positive Quality Intervention in Action: Implementation and Value in Practice

Fay Fieruzeh Ansary and Natasha Olson

effectiveness of therapy. Additionally, healthcare teams are able to ameliorate interprofessional care at the highest level. Conclusion: With NCODA’s creation of PQIs, the vast amount of new oncology information such as updates on new therapeutics, changes in

Full access

A “Shot Heard ’Round the World” on Cancer Drug Costs?

Harold J. Burstein

Recently, members of the pharmacy and therapeutics committee at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York reported that MSKCC will not offer ziv-aflibercept (Zaltrap, Sanofi Oncology) to patients with advanced colorectal cancer at

Full access

The Time Has Come!

Margaret Tempero

When imatinib was approved by the FDA almost 20 years ago, a passionate prediction arose that, going forward, all targeted therapeutics would be approved without regard for the primary site of disease, based solely on the presumed molecular driver

Full access

NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022

Featured Updates to the NCCN Guidelines

Deborah K. Armstrong, Ronald D. Alvarez, Floor J. Backes, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-may Chen, Viola C. Chitiyo, Mihaela Cristea, Maria DeRosa, Eric L. Eisenhauer, David M. Gershenson, Heidi J. Gray, Rachel Grisham, Ardeshir Hakam, Angela Jain, Amer Karam, Gottfried E. Konecny, Charles A. Leath III, Gary Leiserowitz, Joyce Liu, Lainie Martin, Daniela Matei, Michael McHale, Karen McLean, David S. Miller, Sanja Percac-Lima, Steven W. Remmenga, John Schorge, Daphne Stewart, Premal H. Thaker, Roberto Vargas, Andrea Wahner Hendrickson, Theresa L. Werner, Emese Zsiros, Mary A. Dwyer, and Lisa Hang

receiving consulting fees from Seagen Inc. David M. Gershenson, MD, Panel Member, has disclosed serving as a scientific advisor for Genentech, Inc., Onconova Therapeutics, and Verastem Oncology; owning equity interest/stock options in Bristol-Myers Squibb

Full access

Research Priorities in Geriatric Oncology: Addressing the Needs of an Aging Population

Arti Hurria, Supriya Gupta Mohile, and William Dale

rationale for these research directions. Cancer Therapeutics in the Oldest Adults (Ages 75 and Older) Among FDA-approved treatments for cancer, only 9% of patients enrolled in registration trials were 75 years or older, whereas 31% of patients with